+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Embolotherapy Market by Embolic Agent Type, Therapeutic Modality, Embolic Persistence, Access Route, Clinical Application, End User, Patient Age Group - Global Forecast 2026-2032- Product Image
Embolotherapy Market by Embolic Agent Type, Therapeutic Modality, Embolic Persistence, Access Route, Clinical Application, End User, Patient Age Group - Global Forecast 2026-2032- Product Image
Sale

Embolotherapy Market by Embolic Agent Type, Therapeutic Modality, Embolic Persistence, Access Route, Clinical Application, End User, Patient Age Group - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4829978
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Embolotherapy Market is projected to reach USD 4.06 Billion in 2026. It is expected to continue growing at a CAGR of 7.01%, reaching USD 6.11 Billion by 2032.

Embolotherapy is a core interventional radiology discipline that uses image-guided catheter delivery to intentionally occlude blood vessels for therapeutic benefit. Demand is supported by established clinical use in hepatocellular carcinoma through transarterial chemoembolization and radioembolization, uterine fibroid embolization, trauma-related hemorrhage control, gastrointestinal bleeding, vascular malformations, benign prostatic hyperplasia, and preoperative devascularization.

The embolotherapy market is shaped by the shift toward minimally invasive procedures, rising oncology and cardiovascular disease burdens, and broader adoption of embolic agents such as coils, microspheres, particles, plugs, and liquid embolics. Hospitals and ambulatory interventional suites are prioritizing technologies that improve procedural precision, reduce inpatient burden, support repeatable outcomes, and enable safe navigation across complex vascular anatomies.

Transformative Shifts in the Embolotherapy Landscape

The embolotherapy landscape is moving from conventional vessel occlusion toward precision embolization, where device selection is increasingly matched to flow dynamics, lesion biology, and downstream clinical goals. Drug-eluting beads, calibrated microspheres, detachable coils, vascular plugs, and advanced liquid embolics are expanding treatment options while enabling more predictable distribution, controlled deployment, and targeted therapy.

Care delivery is also changing as interventional radiology teams integrate cone-beam CT, fusion imaging, navigation software, and multidisciplinary tumor boards to improve case planning and clinical decision-making. At the same time, reimbursement scrutiny, evidence expectations, and hospital value-analysis committees are pushing suppliers and providers to demonstrate clinical benefit, usability, supply reliability, procedural efficiency, and total cost-of-care advantages.

Cumulative Impact of Artificial Intelligence on Embolotherapy

Artificial intelligence is creating cumulative value across embolotherapy workflows rather than replacing physician judgment. In pre-procedure planning, AI-enabled imaging tools can support lesion detection, vessel segmentation, volumetric assessment, and treatment simulation. During procedures, AI-assisted image reconstruction, radiation-dose optimization, and navigation support can help clinicians manage complex anatomy and reduce workflow variability.

Post-procedure, machine learning can contribute to response assessment by analyzing imaging changes, tumor enhancement patterns, perfusion characteristics, and longitudinal outcomes. The strongest near-term opportunity is decision support that combines imaging, device characteristics, and patient risk factors. Adoption will depend on clinical validation, interoperability with angiography platforms, cybersecurity controls, explainable outputs, and transparent regulatory pathways for software as a medical device.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific is gaining momentum as China, Japan, India, South Korea, and Australia expand interventional oncology, stroke-related vascular care, trauma management, and minimally invasive treatment access. China and India benefit from large patient pools, rising cancer and cardiovascular disease burdens, and hospital infrastructure investment, while Japan and South Korea show strong uptake of advanced image-guided technologies supported by mature imaging capacity and specialist training. Australia’s centralized specialist networks and evidence-based clinical standards support demand for proven embolic devices and workflow solutions.

North America remains a high-adoption region due to established interventional radiology networks, broad availability of embolic devices, advanced angiography infrastructure, and clinical guideline integration. Europe benefits from strong tertiary care systems, oncology programs, specialist societies, and medical device regulation that emphasizes safety, clinical evidence, and post-market surveillance. Latin America is advancing through urban specialty centers in Brazil and Mexico, where private hospital investment and oncology service expansion are improving access, although availability continues to vary by payer coverage, procurement capacity, and trained workforce distribution.

The Middle East is expanding embolotherapy through tertiary hospitals, oncology investment, trauma care development, and medical tourism hubs, particularly across GCC markets. Africa remains more heterogeneous, with adoption concentrated in major referral hospitals and academic centers where imaging infrastructure, trained interventional radiologists, and device availability are improving. Across emerging regions, the most durable progress is linked to workforce training, reliable supply chains, reimbursement clarity, and access to modern angiography systems.

Key Group Insights Across ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are increasingly relevant as Indonesia, Thailand, Malaysia, Singapore, Vietnam, and the Philippines invest in hospital modernization, cancer care capacity, and interventional radiology training. Singapore serves as a regional center for advanced image-guided care and specialist education, while larger ASEAN countries present procedure-volume potential as reimbursement pathways, specialist availability, and public-private hospital investment improve.

The GCC benefits from high healthcare spending, tertiary hospital networks, and strategic investment in oncology, emergency care, and minimally invasive specialties. The European Union provides a structured regulatory and procurement environment, where Medical Device Regulation compliance, clinical evidence, traceability, and post-market surveillance influence market access. BRICS countries combine substantial patient demand with uneven infrastructure maturity, creating opportunities for scalable product portfolios, localized training, and adaptable pricing strategies aligned with hospital capability.

G7 markets remain important for premium embolic agents, clinical research, evidence generation, reimbursement assessment, and early adoption of AI-enabled imaging and navigation. NATO-aligned healthcare systems, while not a commercial market bloc, often share procurement standards, emergency medicine priorities, trauma readiness requirements, and defense-related hemorrhage control needs that can support demand for embolization technologies used in acute bleeding management.

Key Country Insights for Major Embolotherapy Markets

The United States leads in embolotherapy adoption through mature interventional radiology practices, oncology centers, trauma networks, outpatient procedure capabilities, and broad device availability, while Canada emphasizes evidence-based access within provincial healthcare systems and strong tertiary care referral pathways. Mexico and Brazil show growing demand in private hospitals and urban specialty centers, particularly for oncology, gastrointestinal bleeding, trauma, and women’s health applications, with access shaped by payer mix and specialist concentration.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established referral pathways, oncology programs, and strong specialist networks. Germany and France are important hubs for innovation, training, and advanced image-guided procedures, while the United Kingdom emphasizes guideline-driven adoption and health technology assessment. Italy and Spain support demand through active tertiary hospitals and interventional oncology programs. Russia retains demand across major urban hospitals but faces procurement, logistics, and supply-chain constraints that can affect availability of advanced embolic products.

China and India represent major expansion opportunities supported by large cancer and vascular disease burdens, expanding hospital capacity, and increasing interventional radiology training. Japan and South Korea are advanced technology adopters with strong imaging infrastructure, high procedural sophistication, and well-established hospital networks. Australia combines high clinical standards with centralized specialist care and public-private healthcare delivery, supporting demand for proven embolic devices, radiation-conscious imaging workflows, and integrated image-guided treatment solutions.

Actionable Recommendations for Embolotherapy Industry Leaders

Industry vendors should prioritize clinical differentiation by generating real-world evidence, comparative outcome data, and procedure-specific value propositions for oncology, women’s health, trauma, gastrointestinal bleeding, benign prostatic hyperplasia, and vascular malformations. Product portfolios should address both premium precision embolics and cost-effective options for emerging markets without compromising safety, visibility, deliverability, or handling performance.

Manufacturers and providers should invest in physician training, proctoring, simulation, and digital case-planning tools to improve adoption and procedural consistency. Partnerships with hospitals, imaging technology providers, and AI software developers can strengthen ecosystem positioning. Supply-chain resilience, regulatory readiness, reimbursement evidence, post-market surveillance, and cybersecurity for connected workflow tools should be treated as strategic capabilities rather than back-office functions.

Research Methodology for Embolotherapy Market Analysis

The research approach integrates primary and secondary intelligence to evaluate embolotherapy demand drivers, technology adoption, competitive dynamics, clinical use patterns, and regional access conditions. Primary inputs include perspectives from interventional radiologists, hospital procurement stakeholders, clinical specialists, distributors, payers, and medical device executives with direct exposure to embolization procedures and purchasing decisions.

Secondary analysis draws from peer-reviewed clinical literature, regulatory databases, clinical guidelines, procedure coding references, hospital purchasing indicators, public health statistics, adverse event resources, and international disease-burden sources. Findings are validated through data triangulation, market-factor analysis, and consistency checks across procedure utilization signals, installed imaging capacity, regulatory status, reimbursement context, specialist availability, supply-chain conditions, and macroeconomic indicators.

Conclusion: Strategic Outlook for Embolotherapy

Embolotherapy is positioned for sustained relevance as healthcare systems favor targeted, image-guided, minimally invasive treatment strategies that can reduce surgical burden and support organ-preserving care. The market’s strategic importance is reinforced by oncology needs, vascular disease management, trauma care, gastrointestinal bleeding treatment, uterine fibroid management, and expanding acceptance of embolization as a therapeutic alternative or adjunct to surgery.

Future competitiveness will depend on precision delivery, evidence generation, AI-enabled workflow integration, regulatory execution, and regional access strategies. Organizations that align device innovation with clinician training, payer expectations, reliable supply, and measurable patient outcomes will be best positioned to strengthen long-term relevance in the global embolotherapy market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Embolotherapy Market, by Embolic Agent Type
7.1. Coils
7.2. Vascular Plugs
7.3. Detachable Balloons
7.4. Sclerosants
7.5. Liquid Glue
8. Embolotherapy Market, by Therapeutic Modality
8.1. Stent-Assisted Coiling
8.2. Chemoembolization
8.3. Sandwich Technique
9. Embolotherapy Market, by Embolic Persistence
9.1. Temporary Embolics
9.2. Permanent Embolics
10. Embolotherapy Market, by Access Route
10.1. Transarterial
10.2. Transvenous
11. Embolotherapy Market, by Clinical Application
11.1. Oncology
11.2. Neurovascular Disorders
11.3. Peripheral Vascular Disease
11.4. Gynecological Conditions
11.5. Urological Conditions
11.6. Gastrointestinal Bleeding
12. Embolotherapy Market, by End User
12.1. Hospitals
12.2. Ambulatory Surgical Centers
12.3. Specialty Clinics
13. Embolotherapy Market, by Patient Age Group
13.1. Pediatric
13.2. Adult
13.3. Geriatric
14. Asia-Pacific Embolotherapy Market
15. Europe Embolotherapy Market
16. North America Embolotherapy Market
17. Latin America Embolotherapy Market
18. Africa Embolotherapy Market
19. Middle East Embolotherapy Market
20. NATO Embolotherapy Market
21. G7 Embolotherapy Market
22. BRICS Embolotherapy Market
23. European Union Embolotherapy Market
24. ASEAN Embolotherapy Market
25. GCC Embolotherapy Market
26. China Embolotherapy Market
27. United States Embolotherapy Market
28. Japan Embolotherapy Market
29. India Embolotherapy Market
30. Germany Embolotherapy Market
31. United Kingdom Embolotherapy Market
32. Australia Embolotherapy Market
33. France Embolotherapy Market
34. South Korea Embolotherapy Market
35. Italy Embolotherapy Market
36. Canada Embolotherapy Market
37. Russia Embolotherapy Market
38. Brazil Embolotherapy Market
39. Mexico Embolotherapy Market
40. Spain Embolotherapy Market
41. Competitive Landscape
41.1. Market Concentration Analysis, 2025
41.1.1. Concentration Ratio (CR)
41.1.2. Herfindahl Hirschman Index (HHI)
41.2. Recent Developments & Impact Analysis, 2025
41.3. Product Portfolio Analysis, 2025
41.4. Benchmarking Analysis, 2025
42. Company Profiles
42.1. Abbott Laboratories
42.2. ABK Biomedical Inc.
42.3. Acandis GmbH
42.4. Artio Medical Inc.
42.5. B. Braun SE
42.6. Becton, Dickinson and Company
42.7. Boston Scientific Corporation
42.8. Canon Medical Systems Corporation
42.9. Cardinal Health Inc.
42.10. Cook Group Incorporated
42.11. Embolx Inc.
42.12. EndoBar Solutions, LLC
42.13. EndoShape Inc.
42.14. GE HealthCare Technologies Inc.
42.15. Guerbet SA
42.16. IMBiotechnologies Ltd.
42.17. Instylla Inc.
42.18. Johnson & Johnson Services Inc.
42.19. Kaneka Corporation
42.20. Koninklijke Philips N.V.
42.21. Medtronic plc
42.22. Merit Medical Systems Inc.
42.23. Penumbra Inc.
42.24. QT Vascular Ltd.
42.25. Shape Memory Medical Inc.
42.26. Sirtex Medical Limited
42.27. Stryker Corporation
42.28. Surefire Medical Inc.
42.29. Terumo Corporation
42.30. TriSalus Life Sciences Inc.
42.31. Vascular Solutions Inc.
List of Figures
FIGURE 1. GLOBAL EMBOLOTHERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL EMBOLOTHERAPY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL EMBOLOTHERAPY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL EMBOLOTHERAPY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL EMBOLOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL EMBOLOTHERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2032 (%)
FIGURE 17. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2025 VS 2032 (%)
FIGURE 21. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 25. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 27. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. EUROPE EMBOLOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. EUROPE EMBOLOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. AFRICA EMBOLOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. AFRICA EMBOLOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 39. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. NATO EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. NATO EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. G7 EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. G7 EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. ASEAN EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. ASEAN EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. GCC EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 51. GCC EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 52. CHINA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED STATES EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. JAPAN EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. INDIA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. GERMANY EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. UNITED KINGDOM EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. AUSTRALIA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. FRANCE EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. SOUTH KOREA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. ITALY EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. CANADA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. RUSSIA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. BRAZIL EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 65. MEXICO EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 66. SPAIN EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL EMBOLOTHERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL EMBOLOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL EMBOLOTHERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL COILS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL COILS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL COILS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL VASCULAR PLUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL VASCULAR PLUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL VASCULAR PLUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL DETACHABLE BALLOONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL DETACHABLE BALLOONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL DETACHABLE BALLOONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL SCLEROSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL SCLEROSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL SCLEROSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL LIQUID GLUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL LIQUID GLUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL LIQUID GLUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL STENT-ASSISTED COILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL STENT-ASSISTED COILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL STENT-ASSISTED COILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CHEMOEMBOLIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CHEMOEMBOLIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CHEMOEMBOLIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL SANDWICH TECHNIQUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL SANDWICH TECHNIQUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL SANDWICH TECHNIQUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL TEMPORARY EMBOLICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL TEMPORARY EMBOLICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL TEMPORARY EMBOLICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PERMANENT EMBOLICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL PERMANENT EMBOLICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PERMANENT EMBOLICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL TRANSARTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL TRANSARTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL TRANSARTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL TRANSVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL TRANSVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL TRANSVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NEUROVASCULAR DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NEUROVASCULAR DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NEUROVASCULAR DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL PERIPHERAL VASCULAR DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL PERIPHERAL VASCULAR DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PERIPHERAL VASCULAR DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GYNECOLOGICAL CONDITIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GYNECOLOGICAL CONDITIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GYNECOLOGICAL CONDITIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL UROLOGICAL CONDITIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL UROLOGICAL CONDITIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL UROLOGICAL CONDITIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GASTROINTESTINAL BLEEDING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GASTROINTESTINAL BLEEDING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GASTROINTESTINAL BLEEDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 95. EUROPE EMBOLOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. EUROPE EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 97. EUROPE EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 98. EUROPE EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 99. EUROPE EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 100. EUROPE EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 101. EUROPE EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 102. EUROPE EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 119. AFRICA EMBOLOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. AFRICA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 121. AFRICA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 122. AFRICA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 123. AFRICA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 124. AFRICA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 125. AFRICA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 126. AFRICA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 127. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 135. NATO EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. NATO EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 137. NATO EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 138. NATO EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 139. NATO EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 140. NATO EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 141. NATO EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. NATO EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 143. G7 EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 144. G7 EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 145. G7 EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 146. G7 EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 147. G7 EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 148. G7 EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 149. G7 EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. G7 EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 151. BRICS EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 152. BRICS EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 153. BRICS EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 154. BRICS EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 155. BRICS EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 156. BRICS EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 157. BRICS EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. BRICS EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 167. ASEAN EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 168. ASEAN EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 169. ASEAN EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 170. ASEAN EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 171. ASEAN EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 172. ASEAN EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 173. ASEAN EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. ASEAN EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 175. GCC EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 176. GCC EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 177. GCC EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 178. GCC EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 179. GCC EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 180. GCC EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 181. GCC EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. GCC EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 183. CHINA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 184. CHINA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 185. CHINA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 186. CHINA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 187. CHINA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 188. CHINA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 189. CHINA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 190. CHINA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 191. UNITED STATES EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 192. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 193. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 194. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 195. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 196. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 197. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 198. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 199. JAPAN EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 200. JAPAN EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 201. JAPAN EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 202. JAPAN EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 203. JAPAN EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 204. JAPAN EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 205. JAPAN EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 206. JAPAN EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 207. INDIA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 208. INDIA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 209. INDIA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 210. INDIA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 211. INDIA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 212. INDIA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 213. INDIA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 214. INDIA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 215. GERMANY EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 216. GERMANY EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 217. GERMANY EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 218. GERMANY EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 219. GERMANY EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 220. GERMANY EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 221. GERMANY EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 222. GERMANY EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 223. UNITED KINGDOM EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 224. UNITED KINGDOM EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 225. UNITED KINGDOM EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 226. UNITED KINGDOM EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 227. UNITED KINGDOM EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 228. UNITED KINGDOM EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 229. UNITED KINGDOM EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. UNITED KINGDOM EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 231. AUSTRALIA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 232. AUSTRALIA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 233. AUSTRALIA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 234. AUSTRALIA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 235. AUSTRALIA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 236. AUSTRALIA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 237. AUSTRALIA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 238. AUSTRALIA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 239. FRANCE EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 240. FRANCE EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 241. FRANCE EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 242. FRANCE EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 243. FRANCE EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 244. FRANCE EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 245. FRANCE EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 246. FRANCE EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 247. SOUTH KOREA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 248. SOUTH KOREA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 249. SOUTH KOREA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 250. SOUTH KOREA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 251. SOUTH KOREA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 252. SOUTH KOREA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 253. SOUTH KOREA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 254. SOUTH KOREA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 255. ITALY EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 256. ITALY EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 257. ITALY EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 258. ITALY EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 259. ITALY EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 260. ITALY EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 261. ITALY EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 262. ITALY EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 263. CANADA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 264. CANADA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 265. CANADA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 266. CANADA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 267. CANADA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 268. CANADA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 269. CANADA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 270. CANADA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 271. RUSSIA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 272. RUSSIA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 273. RUSSIA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 274. RUSSIA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 275. RUSSIA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 276. RUSSIA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 277. RUSSIA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 278. RUSSIA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 279. BRAZIL EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 280. BRAZIL EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 281. BRAZIL EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 282. BRAZIL EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 283. BRAZIL EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 284. BRAZIL EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 285. BRAZIL EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 286. BRAZIL EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 287. MEXICO EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 288. MEXICO EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 289. MEXICO EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 290. MEXICO EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 291. MEXICO EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 292. MEXICO EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 293. MEXICO EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 294. MEXICO EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 295. SPAIN EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 296. SPAIN EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
TABLE 297. SPAIN EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 298. SPAIN EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
TABLE 299. SPAIN EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
TABLE 300. SPAIN EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
TABLE 301. SPAIN EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 302. SPAIN EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Embolotherapy market report include:
  • Abbott Laboratories
  • ABK Biomedical Inc.
  • Acandis GmbH
  • Artio Medical Inc.
  • B. Braun SE
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Canon Medical Systems Corporation
  • Cardinal Health Inc.
  • Cook Group Incorporated
  • Embolx Inc.
  • EndoBar Solutions, LLC
  • EndoShape Inc.
  • GE HealthCare Technologies Inc.
  • Guerbet SA
  • IMBiotechnologies Ltd.
  • Instylla Inc.
  • Johnson & Johnson Services Inc.
  • Kaneka Corporation
  • Koninklijke Philips N.V.
  • Medtronic plc
  • Merit Medical Systems Inc.
  • Penumbra Inc.
  • QT Vascular Ltd.
  • Shape Memory Medical Inc.
  • Sirtex Medical Limited
  • Stryker Corporation
  • Surefire Medical Inc.
  • Terumo Corporation
  • TriSalus Life Sciences Inc.
  • Vascular Solutions Inc.

Table Information

Report AttributeDetails
No. of Pages189
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 4.06 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.11 Billion
Compound Annual Growth Rate7.0%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Embolotherapy Market Forecast to 2033 - Product Image

Embolotherapy Market Forecast to 2033

  • Report
  • 300 Pages
  • Global
From
Embolotherapy - Global Strategic Business Report - Product Image

Embolotherapy - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
Embolotherapy Market Report 2026 - Product Image

Embolotherapy Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Embolotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Embolotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 190 Pages
  • Global
From
KSA Embolotherapy Market Report: Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030 - Product Image

KSA Embolotherapy Market Report: Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030

  • Report
  • 99 Pages
  • Saudi Arabia
From

About the Embolotherapy Market

Embolotherapy is a minimally invasive medical procedure that involves the use of catheters to deliver therapeutic agents to a specific area of the body. The procedure is used to treat a variety of conditions, including vascular malformations, tumors, and arteriovenous malformations. Catheters are used to deliver embolic agents, such as coils, particles, and glue, to the target area. The catheters are inserted through a small incision in the skin and guided to the target area using imaging techniques such as X-ray, ultrasound, or computed tomography. The embolotherapy market is driven by the increasing prevalence of chronic diseases, the growing demand for minimally invasive procedures, and the availability of advanced catheter technologies. The market is further driven by the increasing adoption of embolotherapy in the treatment of various diseases, such as cancer, cardiovascular diseases, and neurological disorders. Some of the major companies in the embolotherapy market include Boston Scientific Corporation, Cook Medical, Medtronic, Terumo Corporation, Merit Medical Systems, Inc., and BTG plc. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.